Neurology

Eculizumab shows promise in treating juvenile generalized myasthenia gravis

Eculizumab is effective and well tolerated in reducing the disease burden for adolescents with refractory anti-acetylcholine receptor antibody-positive generalized myasthenia gravis, showing significant improvements in disease severity and quality of life over a 26-week period, according to a study. This phase 3, open-label, multicenter study involved 11 adolescents aged 12...